{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:38:55Z","timestamp":1767857935051,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01CA128416"],"award-info":[{"award-number":["U01CA128416"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R56AI108388"],"award-info":[{"award-number":["R56AI108388"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA111359"],"award-info":[{"award-number":["CA111359"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SRI International IR&D"}],"content-domain":{"domain":["arcmedres.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.arcmed.2015.11.007","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T06:48:07Z","timestamp":1448952487000},"page":"642-650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells"],"prefix":"10.1016","volume":"46","author":[{"given":"Denong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Somlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaoti","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Sambucetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2015.11.007_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14796694.1.1.37","article-title":"Cancer biomarkers: knowing the present and predicting the future","volume":"1","author":"Chatterjee","year":"2005","journal-title":"Future Oncol"},{"key":"10.1016\/j.arcmed.2015.11.007_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0065-230X(08)60215-8","article-title":"Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens","volume":"52","author":"Hakomori","year":"1989","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.arcmed.2015.11.007_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-1-4615-1267-7_24","article-title":"Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines","volume":"491","author":"Hakomori","year":"2001","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.arcmed.2015.11.007_bib4","first-page":"2237","article-title":"Possible roles of tumor-associated carbohydrate antigens","volume":"56","author":"Fukuda","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.arcmed.2015.11.007_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrd1751","article-title":"Glycans in cancer and inflammation\u2013potential for therapeutics and diagnostics","volume":"4","author":"Dube","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.arcmed.2015.11.007_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000240634","article-title":"Molecular evolution of specific human antibody against MUC1 mucin results in improved recognition of the antigen on tumor cells","volume":"30","author":"Persson","year":"2009","journal-title":"Tumour Biol"},{"key":"10.1016\/j.arcmed.2015.11.007_bib7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/ejso.2000.0996","article-title":"Circulating anti-CEA antibodies in the sera of patients with breast cancer","volume":"26","author":"Haidopoulos","year":"2000","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.arcmed.2015.11.007_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/(SICI)1097-0215(19970620)74:3<296::AID-IJC11>3.0.CO;2-A","article-title":"Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma","volume":"74","author":"Renkonen","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2015.11.007_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00432-002-0334-5","article-title":"Expression of ABH\/Lewis-related antigens as prognostic factors in patients with breast cancer","volume":"128","author":"Nakagoe","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.arcmed.2015.11.007_bib10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/glycob\/cwn095","article-title":"A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression","volume":"18","author":"Abd Hamid","year":"2008","journal-title":"Glycobiology"},{"key":"10.1016\/j.arcmed.2015.11.007_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2217\/imt.13.126","article-title":"Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1","volume":"5","author":"Vassilaros","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.arcmed.2015.11.007_bib12","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr1505","article-title":"Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]","volume":"8","author":"Apostolopoulos","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.arcmed.2015.11.007_bib13","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1158\/1078-0432.CCR-08-2213","article-title":"A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies","volume":"15","author":"Shibata","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2015.11.007_bib14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0959-8049(94)00447-1","article-title":"Tumour marker CA15-3: possible uses in the routine management of breast cancer","volume":"31A","author":"Tomlinson","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.arcmed.2015.11.007_bib15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1586\/14789450.4.6.741","article-title":"Circulating tumor cells: detection, molecular profiling and future prospects","volume":"4","author":"Jacob","year":"2007","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.arcmed.2015.11.007_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12282-011-0282-5","article-title":"Role of circulating tumor cells and disseminated tumor cells in primary breast cancer","volume":"19","author":"Hayashi","year":"2012","journal-title":"Breast Cancer"},{"key":"10.1016\/j.arcmed.2015.11.007_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-011-1508-0","article-title":"Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced\/inflammatory, and stage IV breast cancer, using a novel detection technology","volume":"128","author":"Somlo","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.arcmed.2015.11.007_bib18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.lungcan.2012.04.005","article-title":"ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy","volume":"77","author":"Das","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.arcmed.2015.11.007_bib19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/cyto.a.21124","article-title":"A new method for high speed, sensitive detection of minimal residual disease","volume":"81","author":"Liu","year":"2012","journal-title":"Cytometry A"},{"key":"10.1016\/j.arcmed.2015.11.007_bib20","first-page":"9","article-title":"Blood group precursor cryptic glyco-epitopes as breast cancer cell surface markers for immune recognition and targeting","author":"Wang","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.arcmed.2015.11.007_bib21","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1021\/bi00764a001","article-title":"Glycoprotein coat of the TA3 cell. Isolation and partial characterization of a sialic acid containing glycoprotein fraction","volume":"11","author":"Codington","year":"1972","journal-title":"Biochemistry"},{"key":"10.1016\/j.arcmed.2015.11.007_bib22","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.5858\/2004-128-1412-FEOHCA","article-title":"Frequent expression of human carcinoma-associated antigen, a mucin-type glycoprotein, in cells of prostatic carcinoma","volume":"128","author":"Li","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.arcmed.2015.11.007_bib23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1309\/02APA6APGL43GCTR","article-title":"Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions","volume":"122","author":"Liang","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.arcmed.2015.11.007_bib24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.5858\/2004-128-785-OOHCAI","article-title":"Overexpression of human carcinoma-associated antigen in urothelial carcinoma of the bladder","volume":"128","author":"Yao","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.arcmed.2015.11.007_bib25","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.0404036101","article-title":"A rare-cell detector for cancer","volume":"101","author":"Krivacic","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.arcmed.2015.11.007_bib26","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bios.2005.12.024","article-title":"High speed detection of circulating tumor cells","volume":"21","author":"Hsieh","year":"2006","journal-title":"Biosens Bioelectron"},{"key":"10.1016\/j.arcmed.2015.11.007_bib27","first-page":"90","article-title":"Immunological studies on blood groups. Structures and immunochemical properties of oligosaccharides from two fractions of blood group substance from ovarian cyst fluid differeing in B, I, and i activities and reactivity toward Concanavalin A","volume":"175","author":"Maisonrouge McAuliffe","year":"1976","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.arcmed.2015.11.007_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0003-9861(76)90487-2","article-title":"Immunochemical studies on blood groups. Heterogeneity of oligosaccharides liberated by degradation with alkaline borohydride of two human ovarian cyst fractions differing in B, I, and i activities and in reactivity toward concanavalin A","volume":"175","author":"Maisonrouge-McAuliffe","year":"1976","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.arcmed.2015.11.007_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0003-9861(76)90486-0","article-title":"Immunochemical studies on blood groups. Fractionation, heterogeneity, and chemical and immunochemical properties of a blood group substance with B, I and i activities purified from human ovarian cyst fluid","volume":"175","author":"Maisonrouge-McAuliffe","year":"1976","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.arcmed.2015.11.007_bib30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1084\/jem.135.6.1247","article-title":"Immunochemical studies on blood groups. LIV. Classification of anti-I and anti-i sera into groups based on reactivity patterns with various antigens related to the blood group A, B,H, Le a, Le b and precursor substances","volume":"135","author":"Feizi","year":"1972","journal-title":"J Exp Med"},{"key":"10.1016\/j.arcmed.2015.11.007_bib31","first-page":"799","article-title":"Blood group antigens. Ii antigens","volume":"68","author":"Feizi","year":"1975","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.arcmed.2015.11.007_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ddr.21063","article-title":"Anti-oligomannose antibodies as potential serum biomarkers of aggressive prostate cancer","volume":"74","author":"Wang","year":"2013","journal-title":"Drug Dev Res"},{"issue":"suppl 2","key":"10.1016\/j.arcmed.2015.11.007_bib33","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.3816\/CBC.2009.s.008","article-title":"Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer","volume":"9","author":"Anders","year":"2009","journal-title":"Breast Cancer"},{"key":"10.1016\/j.arcmed.2015.11.007_bib34","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1200\/JCO.2005.03.3845","article-title":"Molecular classification and molecular forecasting of breast cancer: ready for clinical application?","volume":"23","author":"Brenton","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440915002842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440915002842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T22:28:45Z","timestamp":1653690525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440915002842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0188440915002842"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2015.11.007","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2015.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 IMSS. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}